| |
[摘要]：Effective therapies to reduce the acute symptoms of the pediatric syndrome Kawasaki's disease can prevent the development of future cardiovascular complications, particularly fatal coronary artery aneurysms. The first line of therapy for Kawasaki's disease is generally intravenous immunoglobulin (IVIG); however, issues involving the cost of this treatment and the fact that on increasing proportion of the Kawasaki's disease population demonstrates resistance to IVIG have challenged standard-of-care practices. This review highlights emerging therapeutic strategies for Kawasaki's disease, including IVIG combination therapies, blockers of TNF-alpha, statins and steroids. |
|
